These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 26045549)

  • 81. A novel "delayed start" protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders.
    Cakmak H; Tran ND; Zamah AM; Cedars MI; Rosen MP
    Fertil Steril; 2014 May; 101(5):1308-14. PubMed ID: 24636401
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Clinical efficacy of the gonadotropin-releasing hormone antagonist, ganirelix, in Korean women undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer with recombinant follicle-stimulating hormone.
    Moon SY; Ku SY; Kim SM; Jee BC; Suh CS; Choi YM; Kim JG; Kim SH
    J Obstet Gynaecol Res; 2005 Jun; 31(3):227-35. PubMed ID: 15916659
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Human chorionic gonadotropin vs. gonadotropin-releasing hormone agonist trigger in assisted reproductive technology--"the king is dead, long live the king!".
    Humaidan P; Polyzos NP
    Fertil Steril; 2014 Aug; 102(2):339-41. PubMed ID: 24907915
    [No Abstract]   [Full Text] [Related]  

  • 84. Cumulative Live Birth Rate and Cost-Effectiveness Analysis of Gonadotropin Releasing Hormone-Antagonist Protocol and Multiple Minimal Ovarian Stimulation in Poor Responders.
    Liu Y; Su R; Wu Y
    Front Endocrinol (Lausanne); 2020; 11():605939. PubMed ID: 33519714
    [TBL] [Abstract][Full Text] [Related]  

  • 85. The influence of estradiol/follicle and estradiol/oocyte ratios on the outcome of controlled ovarian stimulation for in vitro fertilization.
    Orvieto R; Zohav E; Scharf S; Rabinson J; Meltcer S; Anteby EY; Homburg R
    Gynecol Endocrinol; 2007 Feb; 23(2):72-5. PubMed ID: 17454155
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Antagonist protocol versus clomiphene in unexplained infertility: A randomized controlled study.
    Nada AM; ElSetohy KA; Banat MM; Shaheen AF
    Taiwan J Obstet Gynecol; 2016 Jun; 55(3):326-30. PubMed ID: 27343309
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
    Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
    Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Repeated doses of GnRH antagonist at midcycle in artificial frozen embryo transfer cycles may not affect pregnancy outcomes.
    Palmerola KL; Hsu JY; Grossman LC; Sauer MV; Lobo RA
    Gynecol Endocrinol; 2017 Apr; 33(4):301-305. PubMed ID: 28010150
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Efficacy of the delayed start antagonist protocol for controlled ovarian stimulation in Bologna poor ovarian responders: a systematic review and meta-analysis.
    Yang S; Liu N; Li Y; Zhang L; Yue R
    Arch Gynecol Obstet; 2021 Feb; 303(2):347-362. PubMed ID: 33236173
    [TBL] [Abstract][Full Text] [Related]  

  • 90. IVF characteristics and the molecular luteal features of random start IVF cycles are not different from conventional cycles in cancer patients.
    Esmaeilian Y; Hela F; Bildik G; Akin N; İltumur E; Yusufoglu S; Yildiz CS; Keles İ; Vatansever D; Taskiran C; Yakin K; Oktem O
    Hum Reprod; 2023 Jan; 38(1):113-124. PubMed ID: 36367834
    [TBL] [Abstract][Full Text] [Related]  

  • 91. A randomized, controlled, pilot trial on the effect of dehydroepiandrosterone on ovarian response markers, ovarian response, and in vitro fertilization outcomes in poor responders.
    Yeung TW; Chai J; Li RH; Lee VC; Ho PC; Ng EH
    Fertil Steril; 2014 Jul; 102(1):108-115.e1. PubMed ID: 24796766
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
    Vuong TN; Phung HT; Ho MT
    Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Flexible GnRH antagonist versus flare-up GnRH agonist protocol in poor responders treated by IVF: a randomized controlled trial.
    Lainas TG; Sfontouris IA; Papanikolaou EG; Zorzovilis JZ; Petsas GK; Lainas GT; Kolibianakis EM
    Hum Reprod; 2008 Jun; 23(6):1355-8. PubMed ID: 18403419
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Large, comparative, randomized double-blind trial confirming noninferiority of pregnancy rates for corifollitropin alfa compared with recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist controlled ovarian stimulation protocol in older patients undergoing in vitro fertilization.
    Boostanfar R; Shapiro B; Levy M; Rosenwaks Z; Witjes H; Stegmann BJ; Elbers J; Gordon K; Mannaerts B;
    Fertil Steril; 2015 Jul; 104(1):94-103.e1. PubMed ID: 26003273
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial.
    Nyboe Andersen A; Nelson SM; Fauser BC; García-Velasco JA; Klein BM; Arce JC;
    Fertil Steril; 2017 Feb; 107(2):387-396.e4. PubMed ID: 27912901
    [TBL] [Abstract][Full Text] [Related]  

  • 96. GnRH antagonist versus long GnRH agonist protocol in poor IVF responders: a randomized clinical trial.
    Prapas Y; Petousis S; Dagklis T; Panagiotidis Y; Papatheodorou A; Assunta I; Prapas N
    Eur J Obstet Gynecol Reprod Biol; 2013 Jan; 166(1):43-6. PubMed ID: 23020996
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Does physicians' experience influence in vitro fertilization success in patients undergoing controlled ovarian hyperstimulation with GnRH antagonists?
    Orvieto R; Rabinson J; Meltcer S; Gemer O; Anteby EY; Zohav E
    Fertil Steril; 2008 Mar; 89(3):736-7. PubMed ID: 17498708
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Comparative study between single versus dual trigger for poor responders in GnRH-antagonist ICSI cycles: A randomized controlled study.
    Maged AM; Ragab MA; Shohayeb A; Saber W; Ekladious S; Hussein EA; El-Mazny A; Hany A
    Int J Gynaecol Obstet; 2021 Mar; 152(3):395-400. PubMed ID: 33011968
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Scheduling GnRH antagonist cycles by a short course of oral estradiol administration during early follicular phase: a comparative study with non-scheduled cycles.
    Aslan K; Avci B; Uncu G; Saribal S; Ata B
    Gynecol Endocrinol; 2015 Jun; 31(6):465-8. PubMed ID: 25982362
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer.
    Doldi N; Persico P; Di Sebastiano F; Marsiglio E; Ferrari A
    Gynecol Endocrinol; 2006 May; 22(5):235-8. PubMed ID: 16785142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.